Fangzhou Inc. (6086) AI Stock Analysis

• Market Cap: HK$2.08B
• Dividend Yield: N/A
• Average Volume (3M): 2.01M
• Price to Earnings (P/E): 87.6
• Beta (1Y): 1.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 488
• Sector: Technology
• Sector Strength: 88
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.01
• Shares Outstanding: 1,385,448,500
• 10 Day Avg. Volume: 2,214,042
• 30 Day Avg. Volume: 2,011,125
• PEG Ratio: -0.03
• Price to Book (P/B): 45.86
• Price to Sales (P/S): 2.23
• P/FCF Ratio: 386.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.03
• Revenue Forecast (FY): HK$4.04B

• Rating: 43 Neutral
• Price Target: HK$3.00 ▼(-17.36% Downside)
• Action: Downgraded Date: 01/28/26
• Date: Action: Downgraded 01/28/26

The score is held down primarily by weak financial fundamentals—ongoing losses and a strained balance sheet with negative equity—despite some improvement in operating cash flow. Technicals are neutral-to-mixed with only a short-term rebound, and valuation remains unattractive due to negative earnings and no dividend support.

Positive Factors

Operating cash flow improvement

A shift to positive operating cash flow is a durable improvement that reduces reliance on external financing and supports ongoing operating needs. For a drug manufacturer, sustained OCF helps fund trials, regulatory work and commercialization without immediate equity or debt raises.

Improved liquidity and liability reduction

Reduction in total liabilities alongside higher cash balances strengthens financial flexibility and lowers short-term solvency risk. This provides the firm more runway to invest in development or restructure operations without immediate distressed financing decisions.

Positive revenue growth

Sustained revenue growth suggests underlying market demand and commercial traction for products or services. For a pharmaceutical company, consistent top-line expansion offers a base to scale margins, justify continued R&D investment and pursue commercialization strategies over months.

Negative Factors

Persistent net losses and negative margins

Ongoing net losses and negative operating margins are structural red flags: they erode retained capital and limit reinvestment capacity. Without a credible pathway to sustained profitability, the company will struggle to fund growth and absorb shocks over the medium term.

Negative equity and high leverage

Negative equity and high leverage materially constrain strategic flexibility, increase refinancing risk, and can limit access to capital. Over months, this heightens insolvency risk and can force dilutive financing or asset sales if cash generation slips.

Weak free cash flow and cash conversion

Low free cash flow and poor cash conversion mean the business cannot reliably turn accounting profits into spendable cash. This limits ability to deleverage, invest in late-stage trials or scale commercial activities without recurring external funding.

Fangzhou Inc. Business Overview & Revenue Model

Company Description

Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies. The company was founded in 2015 and is based in Guangzhou, China.

How the Company Makes Money

Fangzhou Inc. generates revenue through multiple streams, primarily by selling software licenses and subscriptions for its enterprise software products. The company also earns significant income from its cloud computing services, which include hosting and data storage solutions for businesses. Additionally, Fangzhou provides managed IT services and cybersecurity consulting, contributing to its overall revenue. Strategic partnerships with other technology firms enhance Fangzhou's offerings and expand its market reach, while a focus on long-term contracts with clients ensures a steady flow of income. The company also benefits from ongoing maintenance and support agreements, which provide recurring revenue streams.

Fangzhou Inc. Financial Statement Overview

Summary

Income statement performance is weak with persistent net losses and negative EBIT/EBITDA margins despite revenue growth and slightly better gross margin. The balance sheet is stressed with negative equity and high leverage, partly offset by reduced liabilities and improved cash. Cash flow shows improvement with positive operating cash flow in the latest year, but free cash flow and cash conversion remain weak.

Income Statement

Fangzhou Inc. shows a challenging financial performance with consistent net losses and negative EBIT and EBITDA margins over the years. The gross profit margin has slightly improved, but the net profit margin remains negative. Revenue growth is positive, indicating potential, but profitability remains a significant concern.

Balance Sheet

The balance sheet reflects a high debt burden relative to equity, as indicated by the negative stockholders' equity and high debt-to-equity ratio. The equity ratio is low, suggesting financial instability. However, the reduction in total liabilities and improvement in cash and cash equivalents are positive signs.

Cash Flow

Operating cash flow has improved, turning positive in the latest year, which is a positive development. However, free cash flow remains low, and the cash flow ratios indicate a struggle to convert income into cash. The company has managed to improve its cash position, but overall cash flow stability is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.88B	2.71B	2.43B	2.20B	1.76B
Gross Profit	518.72M	515.94M	487.41M	441.20M	262.74M
EBITDA	7.47M	-739.87M	-174.76M	-123.00M	-220.66M
Net Income	-23.68M	-854.88M	-196.79M	-383.30M	-303.96M
Balance Sheet
Total Assets	768.78M	664.09M	521.37M	582.57M	426.54M
Cash, Cash Equivalents and Short-Term Investments	294.17M	261.51M	146.32M	134.91M	84.66M
Total Debt	36.47M	50.89M	49.72M	1.99B	18.27M
Total Liabilities	618.79M	532.39M	2.42B	2.50B	2.07B
Stockholders Equity	149.99M	131.70M	-1.90B	-1.92B	-1.34B
Cash Flow
Free Cash Flow	-13.17M	15.63M	16.63M	-65.42M	-262.72M
Operating Cash Flow	-11.82M	19.54M	22.28M	-59.28M	-246.43M
Investing Cash Flow	-108.95M	-111.51M	16.42M	14.31M	-4.32M
Financing Cash Flow	156.66M	119.62M	-29.31M	82.23M	-11.41M

Fangzhou Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6086, the sentiment is Negative. The current price of 3.63 is above the 20-day moving average (MA) of 2.15, above the 50-day MA of 2.51, and above the 200-day MA of 3.38, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 28.25 is Positive, neither overbought nor oversold. The STOCH value of 18.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6086.

Fangzhou Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	74 Outperform	HK$103.87B	8.04	11.30%	2.70%	-18.07%	-33.27%
1666	68 Neutral	HK$5.38B	4.25	5.98%	4.47%	0.73%	-34.04%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
2186	58 Neutral	HK$9.70B	9.82	2.85%	―	-2.54%	-48.74%
1799	47 Neutral	HK$8.99B	-6.78	-10.01%	―	-32.90%	-152.00%
6086	43 Neutral	HK$2.08B	87.56	-16.81%	―	―	―
0020	41 Neutral	HK$83.49B	-8.30	-14.43%	―	17.96%	46.64%

Fangzhou Inc. Corporate Events

Fangzhou Raises HK$144.3 Million to Speed AI Chronic Disease Platform Expansion

Fangzhou Inc. has completed a placing of 45,181,000 existing shares at HK$3.32 per share to at least six independent investors, followed by a top-up subscription of an equal number of new shares by the vendor, resulting in the issuance of new shares representing about 3.26% of the enlarged share capital. The transaction raised net proceeds of approximately HK$144.3 million, of which around 90% will be deployed to accelerate development, infrastructure, talent recruitment, data capabilities and market rollout of its AI-powered chronic disease management platform, with the remaining 10% earmarked for working capital and general corporate purposes, strengthening Fangzhou’s growth trajectory in digital health and AI-enabled medical services.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Inc. Launches 3.3% Share Placing and Matching Top-Up Subscription

Fangzhou Inc. has entered into a placing and subscription agreement under its general mandate, whereby a major shareholder (the Vendor) will place 45,181,000 existing shares to investors at HK$3.32 per share, and subsequently subscribe for an equivalent number of new shares at the same price. The deal, representing about 3.37% of Fangzhou’s existing share capital and approximately 3.26% on an enlarged basis, is being arranged on a best-effort basis by a sole placing agent and is priced at an 11.94% discount to the last closing price but an 8.50% premium to the recent five-day average, reflecting a balance between near-term market appetite and recent trading levels; completion is conditional on the Hong Kong Stock Exchange granting listing approval for the new shares and successful completion of the placing, implying a modest but targeted capital raising and share-base expansion that may enhance liquidity while maintaining overall ownership structure.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Signals 2025 Return to Profit on Strong Platform Growth

Fangzhou Inc. has issued a positive profit alert, projecting 2025 revenue of approximately RMB3.50 billion to RMB3.55 billion, about 30% higher than the prior year, and a swing to a net profit of RMB7 million to RMB10 million from a net loss before tax of RMB854.9 million in 2024. Management attributes the top-line expansion to continued growth across its consumer-facing healthcare platform, driven by rising patient and doctor engagement, while the return to profitability is being supported by both higher revenue and lower equity-settled share-based expenses, though the figures remain preliminary and unaudited, prompting the company to caution investors until final results are released by the end of March 2026.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Says Tencent Healthcare Tie-Up Is Routine Amid Unusual Share Price Move

Fangzhou Inc. has clarified that its previously announced strategic collaboration with Tencent Healthcare is part of its routine, ordinary business activities and does not represent an exceptional development. Responding to a recent rise in its share price and media coverage of the partnership, the board stated it is unaware of any undisclosed information or factors driving the stock movement, and affirmed there is no inside information requiring disclosure under Hong Kong’s listing and securities regulations, while advising shareholders and potential investors to exercise caution when dealing in its shares.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Inc. Announces Leadership Reshuffle

Fangzhou Inc. has announced significant leadership changes, including the resignation of Mr. Xie Fangmin as Chairman, CEO, and Authorized Representative, effective December 7, 2025. Mr. Xie will transition to a non-executive Director role. Mr. David McKee Hand will take over as Chairman, while Mr. Zhou Feng and Mr. Hand will join the Nomination Committee, with Mr. Zhu Xiaolu as its chairperson. The company will begin a formal search for a new CEO to ensure a smooth transition.

The most recent analyst rating on (HK:6086) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

Fangzhou Inc. Announces Board Composition and Roles

Fangzhou Inc. has announced the composition of its board of directors and their respective roles within the company. The announcement details the members of the board, including executive, non-executive, and independent non-executive directors, and outlines their participation in various board committees such as the Audit, Remuneration, and Nomination Committees. This update reflects the company’s governance structure, which is crucial for maintaining transparency and accountability to its stakeholders.

The most recent analyst rating on (HK:6086) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.